৳ ০.০০
আপনার সব স্বাস্থ্যসেবার সমাধান — এখন এক জায়গাতেই
১০৬৫৭
info@shukhee.com
টেলিকম ভবন, ৫৩/১, বক্স নগর, ঢাকা-১২১৬
৳ ০.০০
১০৬৫৭
info@shukhee.com
টেলিকম ভবন, ৫৩/১, বক্স নগর, ঢাকা-১২১৬


Products
Payment
Delivery
Indications
Ciprofbrate is indicated as an adjunet to diet, exercise and welght reduction for the following:
Treatment of severe hypertriglyceridemia with or without low HDL cholesterol.
. Mixed hyperlipidemia when a statin is contraindicated or not tolerated.
Pharmacology
Ciprofbrate reduces both LDL & VLDL and hence the levels of triglyceride and cholesterol associated with these lipoprotein fractions. It also increases levels of HDL cholesteroL Ciprofbrate is effective in the
treatment of hyperlipidemia associated with high plasma concentrations of LDL and VLOL. There is evidence that treatment with fibrates may reduce coronary heart disease eventts.
Dosage & Administration
Adults: The recommended dose is Ciprofbrate 100 mg per day. This dose should not be exceoded.
Patients with renal insufficieney: In moderate renal impairment [creatinine clearance 30-80 ml/min/'173 m2) it is recommended that dosage be reduced to one tablet every other day. Patients should be
caretully monitored. Ciprofbrate should not be used in severe renal impairment (creatinine clearance <30 ml/min/1.73 m2)
Patients with hepatic insufficiency: Use with caution in patients with impaired hepatie function. Ciprofbrate treatment should be discontinued in case of increased AST and ALT levels to more than 3 times the
upper limit of normal or if cholestatic liver injury is evidenced.
Elderly: As for adults but precautions should be taken for Age more than 70 yoars.
Paediatrie population: Not recommended since satety and efficacy in children has not been established.
Interaction
Other fibrates & HMG CoA reductase inhibitors: As Risk of myopathy, rhabdomyolysis and myoglobinura may be increased it Ciprofbrate is used in combination with other fibrates and HMG CoA reductase
inhibitors.
Oral anticoagulant therapy: Caution should be exercised when Ciprofbrate is taken with oral anticoagulants. Concomitant oral anticoagulant therapy should be given at a reduced dosage and adjusted
according to INR.
.....
Contraindications
. Hypersensitivity to the active substance or to any of the excipients
Severe hepatic impairment
Severe renal impairment [ereatinine clearance <30 ml/min/'173 m2)
Pregnancy and lactation or when pregnancy is suspected
. Concurrent use with anothor fibrate
Side Effects
Headache, Dizziness, Somnolence, Vertigo, Nausea, Vomiting, Diarrhona, Dyspepsia, Abdominal pain, Rash, Alopecia, Myalgia, Fatigue.
Pregnancy & Lactation
There is no evidence that Ciprofbrate is teratogenie but signs of toxicity at high doses were observed in teratogenicity tests in animals. As there are no data on its use in human pregnancy, Ciprofbrate is
contraindicated during pregnancy. As there are no data on its use in lactation, Ciprofbrate is contraindicated in nursing mothers.
Precautions & Warnings
Special warnings: Patients with rare hereditary problems of galactose intolerance, lactose deficiency or glucose-galactose malabsorption should not take this medicine.
Myalgia/myopathy: Patients should be advised to report unexplained musele pain, tenderness or weakness immediately.
Patients with impaired hepatie funetion: Periodic hepatic function tests are recommended (every 3 months for the first 12 months of treatment). Ciprofbrate treatment should be discontinued in case of
increased AST and ALT levels to more than 3 times the upper limit of normal or if cholestatic liver injury is evidenced.
Therapeutic Class
Anti-hypertensive, Other Anti-anginal & Anti-ischaemic drugs
Storage Conditions
Store below 30C. Protect from light and moisture. Keep the medicine out of reach of children.






N/A
N/A




